Skip to main content
Journal cover image

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

Publication ,  Journal Article
McGrail, DJ; Pilié, PG; Rashid, NU; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, AB; Ueno, NT; Ferrarotto, R; Lin, S-Y ...
Published in: Ann Oncol
September 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

September 2021

Volume

32

Issue

9

Start / End Page

1194 / 1197

Location

England

Related Subject Headings

  • Prevalence
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Antibodies, Monoclonal, Humanized
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., … Lin, S.-Y. (2021). Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol, 32(9), 1194–1197. https://doi.org/10.1016/j.annonc.2021.06.017
McGrail, D. J., P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, et al. “Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.Ann Oncol 32, no. 9 (September 2021): 1194–97. https://doi.org/10.1016/j.annonc.2021.06.017.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin S-Y. Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol. 2021 Sep;32(9):1194–1197.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

September 2021

Volume

32

Issue

9

Start / End Page

1194 / 1197

Location

England

Related Subject Headings

  • Prevalence
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Antibodies, Monoclonal, Humanized
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis